FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: generx

Sort
E.g., 2013-05-24
E.g., 2013-05-24
Enter a comma separated list of user names.

Cardium Therapeutics Wins Patents Rights, Settles Competition with Boston Scientific
Posted by OTC Showcase on November 19th, 2012

Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease

Resolves Long-standing Competition with Boston Scientific Corporation Over Rights to Cardiovascular Gene Therapy in the U.S. and Europe

Read More
comment 0
Share
Tags:
Cardium Therapeutics, CXM, cardiovascular disease, gene therapy, Boston Scientific, generx, new treatments for coronary heart disease, dna therapy, regenerative medicine stocks, Excellagen

EC Approval of Glybera A Significant Industry Milestone in Gene Therapy
Posted by OTC Showcase on November 6th, 2012

Commenting on the October 25 approval by the European Commission for its gene therapy, Glybera®, Dutch biotech company uniQure said Monday it plans to start selling Glybera in Europe by mid-2013 and predicted a boom of similar therapies.  The EC approval marks Glybera as the first gene therapy to be approved in the Western world.

“We believe that after Glybera’s approval gene therapy is at the beginning of a period of rapid growth similar to the development of the antibody business in the last decade,” said Joern Aldag, Chief Executive Officer at uniQure.

Read More
comment 0
Share
Tags:
Cardium Therapeutics, CXM, gene therapy, generx, dna therapy, regenerative medicine stocks, Glybera, uniQure

Cardium Therapeutics, Inc. (CXM) Acquisition of To Go Brands Further Taps Growing Supplements Market
Posted by OTC Showcase on November 1st, 2012

Late in September, a comprehensive report by Global Industry Analysts, Inc. stated that the global nutraceutical market will cross $243 Billion by 2015, “owing to consumer desire for leading a healthy life and increasing scientific evidence supporting health foods.”

The research firm also attributes the strong growth rate to an aging population and rising healthcare costs as catalysts for the neutraceutical industry that it calls “one of the brightest spots in a global market suffering from its worst economic crisis.”

Read More
comment 0
Share
Tags:
Cardium Therapeutics, CXM, cardiovascular disease, gene therapy, Diabetic Foot Wounds, diabetic foot ulcers, dna therapy, regenerative medicine stocks, Excellagen, generx, wound care, surgical would care, MedPodium, dna therapy, To Go Brands

Cardium Therapeutics Investor Presentation with To Go Brands Acquisition
Posted by OTC Showcase on October 25th, 2012

Updated Cardium Therapeutics (NYSE MKT: CXM) Investor Presentation including the acquisition of To Go Brands that was announced on October 1, 2012.

The link provided is for SlideShare.  The presentation can also be found on the Cardium Therapeutics website at:  http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations

Read More
comment 0
Share
Tags:
Cardium Therapeutics, CXM, cardiovascular disease, gene therapy, Diabetic Foot Wounds, diabetic foot ulcers, dna therapy, regenerative medicine stocks, Excellagen, generx, wound care, surgical would care, MedPodium, dna therapy, To Go Brands

Excellagen Presentation on Cardium Therapeutics Website
Posted by OTC Showcase on October 24th, 2012

An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website.  The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

Read More
comment 0
Share
Tags:
Cardium Therapeutics, CXM, cardiovascular disease, gene therapy, Diabetic Foot Wounds, diabetic foot ulcers, dna therapy, regenerative medicine stocks, Excellagen, generx, wound care, surgical would care, Noble Financial, MedPodium, dna therapy, To Go Brands

Cardium Therapeutics Releases New Excellagen Case Studies
Posted by OTC Showcase on August 14th, 2012

Cardium Therapeutics (NYSE MKT: CXM) has released new case study information on its Excellagen wound care management product.

Read More
comment 0
Share
Tags:
Cardium Therapeutics, CXM, cardiovascular disease, gene therapy, Diabetic Foot Wounds, diabetic foot ulcers, dna therapy, regenerative medicine stocks, Excellagen, generx

Cardium CEO Discusses Generx, Excellagen and MedPodium with CEOCFOInterviews.com
Posted by OTC Showcase on July 16th, 2012

Read More
comment 0
Share
Tags:
cardiovascular disease, Cardium Therapeutics, Cell Therapy, chronic wound care, CXM, diabetic foot ulcers, diabetic ulcers, diabetic wounds, dna therapy, Excellagen, gene therapy, generx, regenerative medicine, stem cells, MedPodium, coronary artery disease

Cardium Therapeutics Presents at Marcum MicroCap Conference 2012 Video
Posted by OTC Showcase on July 13th, 2012

Christopher J. Reinhard, Chairman & CEO presented at the Marcum MicroCap Conference on June 20, 2012 at at the Roosevelt Hotel in New York City. In the presentation, Mr. Reinhard details Cardium products, including Generx as a product candidate for advanced coronary artery disease, Excellagen for wound care management and the company’s line of MedPodium neutraceuticals,metabolics and aesthetics.

Read More
comment 0
Share
Tags:
cardiovascular disease, Cardium Therapeutics, Cell Therapy, chronic wound care, CXM, diabetic foot ulcers, diabetic ulcers, diabetic wounds, dna therapy, Excellagen, gene therapy, generx, regenerative medicine, stem cells, MedPodium, coronary artery disease

ADVERTISE WITH US